Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 4/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464533 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2LTA4HHRH3CHRM2 | |
| SCHEMBL429374 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2LTA4HPTGS1PTGS2 | |
| SCHEMBL6268349 | 0.78 | LTA4H (0.44) | ALDH1A1SMN1; SMN2LTA4HPTGS2HRH3 | |
| SCHEMBL20423878 | 0.75 | NFE2L2 (0.55) | MAOB | |
| SCHEMBL18151593 | 0.73 | MAPT (0.39) | ALDH1A1KDM4EMEN1KMT2AMAOB | |
| SCHEMBL16799608 | 0.73 | NFE2L2 (0.44) | MAOB | |
| SCHEMBL3893600 | 0.72 | RORC (0.46) | ALDH1A1PTGS1KDM4EMEN1KMT2A | |
| SCHEMBL18151415 | 0.71 | CYP1A2 (0.41) | ALDH1A1CHRM2HTR1ADRD3SLC6A3 | |
| SCHEMBL426819 | 0.70 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2LTA4HHRH3CHRM2 | |
| SCHEMBL23724061 | 0.70 | LTA4H (0.87) | LTA4HPTGS1PTGS2HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084784-B2 | ROR-gamma modulators and uses thereof | Piramal Enterprises Limited (IN) | 2021-08-10 | — | — | US | disclosed |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2018-08-02 | — | — | US | disclosed |
| EP-3122721-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015145371-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ALDH1A1 389/4885SMN1; SMN2 1447/4885LTA4H 500/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ALDH1A1 261/4885SMN1; SMN2 2090/4885LTA4H 339/4885 |
| US-11084784-B2 | ROR-gamma modulators and uses thereof | RORB, RORA, RORC | ALDH1A1 902/4885SMN1; SMN2 1625/4885LTA4H 1638/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | ALDH1A1 327/4885SMN1; SMN2 1829/4885LTA4H 417/4885 |
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | ALDH1A1 326/4885SMN1; SMN2 2119/4885LTA4H 342/4885 |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | RORB, RORA, RORC | ALDH1A1 902/4885SMN1; SMN2 1625/4885LTA4H 1638/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ALDH1A1 389/4885SMN1; SMN2 1447/4885LTA4H 500/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ALDH1A1 261/4885SMN1; SMN2 2090/4885LTA4H 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.